MyFiziq (ASX:MYQ) - CEO, Vlado Bosanac
CEO, Vlado Bosanac
Source: Balance The Grind
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • MyFiziq (MYQ) has been granted an increased Singaporean patent protection for its body scanning tech
  • MyFiziq’s technology uses a combination of computer vision, patented algorithms, and machine learning to process a 3D avatar of the user with accurate body measurements
  • The company now has patents in Singapore, Australia, the U.S., Hong Kong, Canada, Japan, China, and Korea
  • MyFiziq is up a slight 1.85 per cent on the market and shares are trading for 27.5 cents each

MyFiziq (MYQ) has been granted an increased Singaporean patent protection for its body scanning tech.

MyFiziq’s technology is embedded into an app that uses pictures on the users smartphone to create a 3D avatar with accurate body measurements.

It uses a combination of computer vision, patented algorithms and machine learning to process the images and create the avatar.

The company now has patents in Singapore, Australia, the U.S., Hong Kong, Canada, Japan, China, and Korea.

“This patent is a great addition as we move to progress our recently announced partners in Singapore. MyFiziq is pursuing the divisional patent extensions in all jurisdictions as patent protection is a very important component in our global growth,” CEO Vlado Bosanac commented.

“Being able to defend our intellectual property (IP) is paramount to the evolution of our product and the value we intent to create for our shareholders. Furthermore, IP protection is always an integral part of our discussions with potential investors and underwrites as we progress our NASDAQ process,” he added.

MyFiziq is up a slight 1.85 per cent on the market and shares are trading for 27.5 cents each at 12:01 pm AEST.

MYQ by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Unith wraps up Q1 with $5M in cash as digital humans evolve

Unith has wrapped up Q1 of 2024 with nearly $5M in cash and opex reduced. But…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…